EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Retinoid X receptor agonist 9CDHRA mitigates retinal ganglion cell apoptosis and neuroinflammation in a mouse model of glaucoma

Devaraj Basavarajappa iD, Nitin Chitranshi iD, Seyed Shahab Oddin Mirshahvaladi iD, Veer B Gupta iD, Viswanthram Palanivel iD, Gabriella E Parrilla iD, Akanksha Salkar iD, Mehdi Mirzaei iD, András M Komáromy iD, Wojciech Krezel iD, Stuart L Graham iD, Vivek Gupta iD

The FASEB Journal · 31.03.2025 · 39 (6)

DOI: 10.1096/fj.202402642r ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, online erschienen am 13.03.2025. Verfasst von Devaraj Basavarajappa und 11 weiteren Autor:innen. Beteiligte Einrichtung: Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Retinal Ganglion Cells, Glaucoma, Apoptosis, Retinoid X Receptors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: DHAC | National Health and Medical Research Council (NHMRC), Australian Vision Research (AVR), National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glaucoma, a leading cause of irreversible blindness, is characterized by the progressive loss of retinal ganglion cells (RGCs) and optic nerve damage, often associated with elevated intraocular pressure (IOP). Retinoid X receptors (RXRs) are ligand‐activated transcription factors crucial for neuroprotection, as they regulate gene expression to promote neuronal survival via several biochemical networks and reduce neuroinflammation. This study investigated the therapeutic potential of 9‐cis‐13,14‐dihydroretinoic acid (9CDHRA), an endogenous retinoid RXR agonist, in mitigating RGC degeneration in a high‐IOP‐induced experimental model of glaucoma. We administered 9CDHRA to glaucomatous mice eyes via intravitreal injections and assessed its effects on endoplasmic reticulum (ER) stress markers, glial cell activation, and RGC survival. Our findings demonstrated that 9CDHRA treatment significantly protected inner retinal function and retinal laminar structure in high‐IOP glaucoma. The treatment reduced ER stress markers, increased protein lysine acetylation, and diminished glial cell activation, leading to a significant decrease in apoptotic cells under glaucomatous conditions. These results suggest that 9CDHRA exerts neuroprotective effects by modulating key pathogenic pathways in glaucoma, highlighting its potential as a novel therapeutic strategy for preserving vision in glaucoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Retinal Ganglion CellsGlaucomaApoptosisRetinoid X ReceptorsNeuroinflammatory DiseasesTretinoinAnimalsMiceDisease Models, AnimalMice, Inbred C57BLEndoplasmic Reticulum StressMaleIntraocular PressureNeuroprotective Agents

Stichwörter der Autor:innen

9CDHRAER stressapoptosisglaucomaglial cellintraocular pressureneuroinflammationneuroprotectionretinoid X receptors

Substanzen

Retinoid X ReceptorsNeuroprotective AgentsTretinoin

Autor:innen und Institutionen

  • Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia.
  • School of Medicine, Deakin University, Geelong, Victoria, Australia.
  • Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, USA.
  • Institut de Génétique et de Biologie Moléculaire et Cellulaire, Institut de la Santé et de la Recherche Médicale (U1258), Centre National de la Recherche Scientifique (UMR7104), Université de Strasbourg, Fédération de M…

ORCID-Profile: Devaraj Basavarajappa, Nitin Chitranshi, Seyed Shahab Oddin Mirshahvaladi, Veer B Gupta, Viswanthram Palanivel, Gabriella E Parrilla, Akanksha Salkar, Mehdi Mirzaei, András M Komáromy, Wojciech Krezel, Stuart L Graham, Vivek Gupta

Förderung

  • DHAC | National Health and Medical Research Council (NHMRC)
  • Australian Vision Research (AVR)
  • National Health and Medical Research Council

Zitieren

APA

Basavarajappa, D., Chitranshi, N., Oddin Mirshahvaladi, S. S., Gupta, V. B., Palanivel, V., Parrilla, G. E., Salkar, A., Mirzaei, M., Komáromy, A. M., Krezel, W., Graham, S. L., & Gupta, V. (2025). Retinoid X receptor agonist 9CDHRA mitigates retinal ganglion cell apoptosis and neuroinflammation in a mouse model of glaucoma. The FASEB Journal, 39(6). https://doi.org/10.1096/fj.202402642r

Vancouver

Basavarajappa D, Chitranshi N, Oddin Mirshahvaladi SS, Gupta VB, Palanivel V, Parrilla GE, et al. Retinoid X receptor agonist 9CDHRA mitigates retinal ganglion cell apoptosis and neuroinflammation in a mouse model of glaucoma. The FASEB Journal. 2025;39(6). doi:10.1096/fj.202402642r

BibTeX
@article{Basavarajappa2025,
  author = {Basavarajappa, Devaraj and Chitranshi, Nitin and Oddin Mirshahvaladi, Seyed Shahab and Gupta, Veer B and Palanivel, Viswanthram and Parrilla, Gabriella E and Salkar, Akanksha and Mirzaei, Mehdi and Komáromy, András M and Krezel, Wojciech and Graham, Stuart L and Gupta, Vivek},
  title = {Retinoid X receptor agonist 9CDHRA mitigates retinal ganglion cell apoptosis and neuroinflammation in a mouse model of glaucoma},
  journal = {The FASEB Journal},
  year = {2025},
  volume = {39},
  number = {6},
  doi = {10.1096/fj.202402642r}
}
Kostenlos starten →